SPHK1 and acute myeloid leukemia: In addition to the sensitizing effect of SPHK1 inhibitor MP-A08 in combination with venetoclax discussed earlier [142], a new study also evaluated the effect of C6-ceramide nanoliposomes in combination with the venetoclax/cytarabine regimen in vitro in AML cell lines, ex vivo in AML patients samples, and in vivo in immunodeficient NRG and immunocompetent syngeneic mouse models [211].